Methods and compositions for treating mammalian nerve tissue injuries
First Claim
1. A method for treating a mammalian patient having suffered an injury to its spinal cord or sciatic nerve, the method comprising administering an effective amount of a composition comprising at least one polyalkylene glycol selected from the group consisting of polmethylene glycol, polyethylene glycol, polypropylene glycol, polybutylene glycol, polypentylene glycol, polyhexylene glycol, polyheptylene glycol, polyoctylene glycol, polynonylene glycol, and polydecylene glycol, and branched and structural isomers thereof to the patient so that the polyalkylene glycol is delivered by way of the patient'"'"'s vascular system to the site of the injured spinal cord or sciatic nerve tissue,wherein delivery by way of the patient'"'"'s vascular system is effected using a technique selected from the group consisting of intravascular, intramuscular, subcutaneous, and intraperitoneal injection, andwherein the polyalkylene glycol is at least about 30% by weight in the composition.
2 Assignments
0 Petitions
Accused Products
Abstract
To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be preformed by directly contacting the agent with the nerve tissue at the site of the injury. Alternatively, the biomembrane fusion agent is delivered to the site of the injury through the blood supply after administration of the biomembrane fusion agent to the patient. The administration is preferably by parenteral administration including intravascular, intramuscular, subcutaneous, or intraperitoneal injection of an effective quantity of the biomembrane fusion agent so that an effective amount is delivered to the site of the nerve tissue injury.
-
Citations
16 Claims
-
1. A method for treating a mammalian patient having suffered an injury to its spinal cord or sciatic nerve, the method comprising administering an effective amount of a composition comprising at least one polyalkylene glycol selected from the group consisting of polmethylene glycol, polyethylene glycol, polypropylene glycol, polybutylene glycol, polypentylene glycol, polyhexylene glycol, polyheptylene glycol, polyoctylene glycol, polynonylene glycol, and polydecylene glycol, and branched and structural isomers thereof to the patient so that the polyalkylene glycol is delivered by way of the patient'"'"'s vascular system to the site of the injured spinal cord or sciatic nerve tissue,
wherein delivery by way of the patient'"'"'s vascular system is effected using a technique selected from the group consisting of intravascular, intramuscular, subcutaneous, and intraperitoneal injection, and wherein the polyalkylene glycol is at least about 30% by weight in the composition.
-
16. A method for treating a mammalian patient having suffered an injury to its spinal cord or sciatic nerve, the method comprising administering an effective amount of a composition comprising at least one polyalkylene glycol selected from the group consisting of polymethylene glycol, polyethylene glycol, polypropylene glycol, polybutylene glycol, polypentylene glycol, polyhexylene glycol, polyheptylene glycol, polyoctylene glycol, polynonylene glycol, and polydecylene glycol, and branched and structural isomers thereof to the patient so that the polyalkylene glycol is delivered by way of the patient'"'"'s vascular system to the site of the injured spinal cord or sciatic nerve tissue,
wherein delivery by way of the patient'"'"'s vascular system is effected using a technique selected from the group consisting of intravascular, intramuscular, subcutaneous, and intraperitoneal injection, wherein the polyalkylene glycol is at least about 30% by weight in the composition; - and
wherein the polyalkylene glycol adheres to the injured spinal cord or sciatic nerve tissue.
- and
Specification